A cross-sectional study of olfactory and taste disorders among COVID-19 patients in China

To determine the prevalence and clinical features of olfactory and taste disorders among coronavirus disease 2019(COVID-19)patients in China.A cross-sectional study was performed in Wuhan from April 3,2020 to April 15,2020.A total of 187 patients with confirmed severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)completed face-to-face interviews or telephone follow-ups.We found that the prevalence of olfactory and taste disorders was significantly lower in the Chinese cohort than in foreign COVID-19 cohorts.Females were more prone to olfactory and taste disorders.In some patients,olfactory and taste disorders precede other symptoms and can be used as early screening and warning signs.

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer

In recent years,immune checkpoint inhibitors(ICIs)have made breakthroughs in the field of lung cancer and have become a focal point for research.Programmed death-1(PD-1)or programmed death-ligand 1(PD-L1)inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer(NSCLC).However,owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon,it may not meet clinical needs.To expand the beneficial range of immunotherapy and improve its efficacy,several research strategies have adopted the use of combination immunotherapy.At present,multiple strategies,such as PD-1/PD-L1 inhibitors combined with chemotherapy,anti-angiogenic therapy,cytotoxic T-lymphocyte-associated protein 4 inhibitors,and radiotherapy,as well as combined treatment with new target drugs,have been evaluated for clinical practice.To further understand the current status and future development direction of immunotherapy,herein,we review the recent progress of ICI combination therapies for NSCLC.